Why Novo Nordisk slashed prices of its weight-loss drug in India: 5 key points

Core Insights - Novo Nordisk has reduced the price of its weight-loss drug Wegovy by up to 33% in India to enhance accessibility and protect its market share amid increasing competition [1] Company Summary - The price cut for Wegovy is a strategic move by Novo Nordisk to expand its customer base in India [1] - This decision reflects the company's response to competitive pressures in the weight-loss drug market [1] Industry Summary - The reduction in drug pricing is indicative of a broader trend in the pharmaceutical industry where companies are adjusting prices to maintain market presence [1] - The weight-loss drug market is becoming increasingly competitive, prompting companies to adopt pricing strategies to attract more consumers [1]